Abstract 395P
Background
Google Trends, a free web-based tracking system of Google search volumes, can be used to monitor online interest in various health conditions, including lung cancer. This is particularly useful in the Philippines, the country named as the world's number one internet user in 2018. Understanding the pattern of information-seeking behavior of Filipinos with regards to lung cancer is crucial because it may inform public policy and potentially make lung cancer awareness campaigns more directed and effective in the population-based setting. Here we described patterns in online search behaviors related to lung cancer using Google Trends data on Google web and YouTube searches in the Philippines for the past ten years.
Methods
Relative search volumes on the term “lung cancer” from 2009 to 2019 were extracted from Google Trends. Both Google web search and YouTube search data were downloaded. The data were saved in a comma-separated values file then imported to Microsoft Excel where a graph was plotted and a polynomial trendline (second order) was added to estimate search trends over a time period. Regions and cities in the Philippines where the term “lung cancer” was most popular were identified. Related topics and queries were also enumerated.
Results
Trends in Google web search showed a steady interest in lung cancer for both Google web search and YouTube searches from 2009 to 2019, with peaks in 2014. No spikes were observed in August, the Philippines’ Lung Cancer Awareness month. Online search behaviour for lung cancer was greatest in Metro Manila and areas in Northern Philippines. Top related and rising topics and queries in lung cancer, both on Google web search and YouTube, were related to etiology, symptoms, and management of lung cancer.
Conclusions
Filipinos had a steady interest in lung cancer, as shown by Google Trends data for both Google web search and YouTube searches from 2009 to 2019. Cancer diagnoses of Filipino personalities in 2014 may have led to peaks in online interest. Filipinos were also interested to learn about etiology, symptoms, and management of lung cancer. These data may be used to leverage online interest to optimize lung cancer awareness campaigns in the Philippines.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract